Connect with us

Technology

Cypherpunk Technologies Reports Second Quarter 2026 Financial Results

Published

3 months ago

on

CAMBRIDGE, Mass., Aug. 12, 2026 /PRNewswire/ — Cypherpunk Technologies Inc., (Nasdaq: CYPH) (“Cypherpunk”), today reported financial results for the second quarter ended June 30, 2026.

“In the second quarter, Cypherpunk built upon the momentum established earlier this year through the disciplined execution of our Zcash digital asset treasury strategy, increasing our treasury holdings to 323,394.38 ZEC, and welcoming Dev Ojha, founder of Valar Group, as an Advisor,” said Douglas E. Onsi, President and CEO of Cypherpunk Technologies. “Our Leap Therapeutics subsidiary reached alignment with the FDA on a proposed Phase 3 trial in a DKK1-high, second-line, metastatic colorectal cancer population, with objective response rate as the primary endpoint to support accelerated approval and overall survival to support full approval in the United States and registration globally. We are conducting a strategic process to determine the best path to advance sirexatamab, whether as an independently financed spin-out company or with a partner who shares our commitment to cancer patients.”

“In an increasingly AI-driven economy, the demand for true privacy is moving from a technical preference to a civilizational necessity. Our execution in the second quarter reinforces Cypherpunk’s conviction in Zcash as a foundational monetary asset. By growing our ZEC treasury, expanding our world-class advisory team, and continuing to back core infrastructure developers like ZODL, we are systematically positioning Cypherpunk to capture the long-term value of digital privacy adoption,” said Will McEvoy, Chief Investment Officer of Cypherpunk.

Cypherpunk Highlights:

Zcash treasury holdings increased to 323,394.38 ZECAs of August 11, 2026, Cypherpunk held a total of 323,394.38 ZEC at an average purchase price of $341.83, representing approximately 1.92% of the total circulating supply of the Zcash network.ZEC is a digital currency that can be transmitted over a peer-to-peer payment system. Zcash uses a cryptographic method called “zero-knowledge proofs” to allow users to engage in financial transactions while maintaining greater privacy.Dev Ojha Appointed as an AdvisorCypherpunk appointed Dev Ojha, the founder of Valar Group, a leading development and research team focused on the Zcash Network, as an Advisor. Valar Group has taken a significant role in developing Zakura, a high-performance full node software designed for massive scalability of Zcash, and on the Ironwood shielded pool. Dev also serves as an official ZIP Editor for Zcash protocol standards. Cypherpunk’s Advisory Team also includes: Arjun Khemani, Zcash key opinion leader; Josh Swihart, CEO of ZODL; Jeff Tiller, Chief of Staff of Gemini; and Zooko Wilcox, Founder of Zcash and Chief Product Officer at Shielded Labs.

Leap Therapeutics Subsidiary Highlights:

Publication of randomized Phase 2 DeFianCe study in Clinical Cancer Research Leap Therapeutics announced the publication of results from the randomized Phase 2 DeFianCe (NCT05480306) study of sirexatamab (DKN-01), an anti-DKK1 monoclonal antibody, in Clinical Cancer Research. The publication, “Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial,” reported the complete efficacy, safety, and biomarker analyses from the study and details the statistical basis for the DKK1 biomarker finding.The peer-reviewed analyses establish that, while the prespecified primary endpoint was not met in the intent-to-treat population, the benefit of sirexatamab increases as a patient’s baseline plasma DKK1 level rises — a relationship confirmed by independent statistical approaches and reinforced by the observation that high DKK1 predicts poorer outcomes on standard of care alone. Together, these findings define DKK1-high metastatic colorectal cancer (mCRC) as a biologically distinct population with high unmet need.Reached FDA alignment on registrational Phase 3 trial in DKK1-high colorectal cancer Leap Therapeutics held a Type C meeting with the FDA to discuss the DeFianCe results and proposed registrational path for sirexatamab in DKK1-high, second-line mCRC. Leap presented its proposed Phase 3 trial design, and the FDA provided feedback supporting key elements of that design, including the use of a DKK1 biomarker-selected patient population and a dual-endpoint structure intended to support both accelerated and full approval.Leap Therapeutics reached alignment with the FDA on a randomized, controlled Phase 3 trial evaluating sirexatamab in combination with investigator’s-choice fluoropyrimidine-based chemotherapy (FOLFIRI or mFOLFOX6) plus bevacizumab, compared with chemotherapy and bevacizumab alone. Approximately 270 patients with mCRC whose disease has progressed following one prior line of systemic therapy prospectively identified as DKK1-high using a baseline plasma DKK1 assay cut point are expected to be enrolled and randomized 1:1. Potential accelerated approval in the United States could be determined by objective response rate (ORR) in an initial group of approximately 160 patients, and overall survival (OS) will be evaluated in the full study population intended to support a filing for full approval in the United States and to support registration in markets outside the United States.A blood-based companion diagnostic would be developed in parallel to identify DKK1-high patients in routine clinical practice.Sirexatamab received Fast Track designation from FDAIn May 2026, the FDA granted Fast Track designation to sirexatamab in combination with fluoropyrimidine plus oxaliplatin- or irinotecan-based chemotherapy and bevacizumab, for the treatment of patients with DKK1-high mCRC whose disease has progressed following one prior systemic therapy.The Fast Track program is intended to facilitate the development and expedite the review of drug candidates and vaccines that treat serious conditions and fill an unmet medical need. Programs with Fast Track designation may benefit from frequent communication with the FDA, in addition to a rolling submission of the marketing application.Business updateLeap Therapeutics has initiated a strategic process to identify the best path forward for sirexatamab and to secure the resources required to advance the program into Phase 3 development. The process is expected to consider a range of alternatives, which may include financing the program as an independent entity, or a strategic transaction with a pharmaceutical or biotechnology company, including a partnership, license, collaboration, sale, or other business combination.There can be no assurance that the strategic process will result in any transaction or financing, or that any transaction or financing that is completed will be on terms favorable to the Company or its stockholders. The Company has not set a timetable for the conclusion of the process and does not intend to disclose developments unless and until it determines that further disclosure is appropriate or required.

Selected Second Quarter 2026 Financial Results

Net income was $39.4 million, or $0.18 per diluted share, for the second quarter of 2026, compared to a net loss of $16.6 million for the second quarter of 2025. The change was primarily due to a $46.0 million unrealized gain on the fair value of the Company’s ZEC treasury holdings during the second quarter of 2026, which are marked to market at the end of each period. During the second quarter of 2026, the price of ZEC increased from $243.35 to $400.09.

Research and development expenses were $0.2 million for the three months ended June 30, 2026, compared to $10.5 million for the same period in 2025. The decrease was primarily due to a decrease in clinical trial and manufacturing expenses due to the completion of the clinical trials, together with a decrease in payroll and related expenses associated with the 2025 reduction in force.

General and administrative expenses were $4.5 million for the three months ended June 30, 2026, compared to $1.8 million for the same period in 2025. The increase of $2.7 million for the three months ended June 30, 2026 was primarily due to a $1.7 million increase in stock-based compensation related to restricted stock units granted to general and administrative employees and directors in the fourth quarter of 2025, a $0.8 million increase in payroll and related expenses, and a $0.2 million increase in professional fees.

During the three months ended June 30, 2026, the Company recorded a $46.0 million unrealized gain on the change in fair value of the Company’s ZEC treasury holdings as the price of ZEC increased during the second quarter of 2026 from $243.35 to $400.09.

Cash and cash equivalents totaled $7.6 million on June 30, 2026, and ZEC treasury holdings, categorized as digital asset receivable, totaled $129.4 million based on the ZEC price of $400.09 on June 30, 2026.

About Cypherpunk

Cypherpunk Technologies is a privacy technology company. The Company’s mission is to advance technologies that guarantee privacy for humans on the internet. Cypherpunk pursues this mission through two primary strategies: accumulating Zcash (ZEC); and investing in, acquiring, and building technologies that push the frontier of privacy forward. Additionally, through its subsidiary Leap Therapeutics, the Company is developing novel therapies for patients with cancer, continuing the development of sirexatamab and FL-501. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov.

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the value of the Company’s ZEC holdings, the investment in Zcash Open Development Labs (“ZODL”), or digital assets held or to be held by the Company, the expected future market, price, and liquidity of ZEC or other digital assets the Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) risks relating to the Company’s operations and business, including the highly volatile nature of the price of ZEC; (b) the risk that material changes in the price of ZEC, such as decreases in price, will result in significant changes to the Company’s financial statements, such as unrealized losses on fair value of ZEC holdings and net loss; (c) the risk that the price of the Company’s common stock may be highly correlated to the price of ZEC; (d) the risk that the Company will fail to realize the anticipated benefits of the ZEC digital asset treasury strategy or the investment in ZODL; (e) risks related to the custody of our ZEC and our reliance on Gemini Space Station and its affiliates for trading and custody services; (f) changes in business, market, financial, political and regulatory conditions; (g) risks related to increased competition in the industries in which the Company does and will operate; (h) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; (i) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and (j) the Company’s ability to comply with the continued listing requirements of the Nasdaq Capital Market.

With respect to our biotechnology operations, important factors that could cause actual results to differ materially from our plans, estimates or expectations could include, but are not limited to: (i) the DeFianCe study did not meet its prespecified primary endpoint of progression-free survival in the intent-to-treat population; (ii) the DKK1 biomarker subgroup and interaction analyses were exploratory, were based on a limited number of patients, were not adjusted for multiplicity, and may not be replicated in a prospective clinical trial; (iii) the impact of imbalances between treatment arms in the DKK1 subgroups; (iv) the risk that alignment with the FDA on trial design does not constitute agreement that any trial will succeed or that any marketing application will be accepted or approved, and the FDA may change its position at any time; (v) accelerated approval, if pursued, requires that the surrogate endpoint be reasonably likely to predict clinical benefit and is subject to confirmatory trial requirements and possible withdrawal if such requirements are not satisfied; (vi) the Company’s ability to initiate or complete the Phase 3 trial on the anticipated timeline or at all; (vii) the Company’s ability to obtain additional capital to advance sirexatamab on acceptable terms or at all; (viii) that risk that the strategic process may not result in any transaction or financing, may be terminated at any time, and any resulting transaction may not be on terms favorable to the Company or its stockholders; (ix) the Company’s ability to develop and validate a companion diagnostic; (x) the success of competing therapies; (xi) the Company’s ability to secure manufacturing capacity for sirexatamab; and (xii) the Company’s ability to maintain and protect its intellectual property rights.

New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Cypherpunk Technologies Inc.

Consolidated Balance Sheets

(in thousands, except share and per share amounts)

June 30, 

December 31, 

2026

2025

(Unaudited)

Assets

Current assets:

Cash and cash equivalents

$           7,624

$         14,035

Digital assets receivable

1,29,387

1,47,404

Research and development incentive receivable

–

602

Prepaid expenses and other current assets

539

40

Total current assets

1,37,550

1,62,081

Right of use assets, net

38

38

Deferred costs

348

401

Deposits

33

662

Other investment

5,000

–

Total assets

$       1,42,969

$       1,63,182

Liabilities and Stockholders’ Equity 

Current liabilities:

Accounts payable

$              588

$           1,981

Accrued expenses

1,014

2,067

Income tax payable

97

472

Lease liability 

38

38

Total current liabilities

1,737

4,558

Non-current liabilities:

Deferred tax liability

1,913

5,118

Total liabilities

3,650

9,676

Stockholders’ equity:

Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 shares issued
    and outstanding as of June 30, 2026 and December 31, 2025, respectively

–

–

Common stock, $0.001 par value; 490,000,000 shares authorized; 107,764,382 and 83,851,051
  shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively

108

84

Stock subscription receivable

–

(150)

Additional paid-in capital

6,39,618

6,16,216

Accumulated other comprehensive loss

(81)

(95)

Accumulated deficit 

(5,00,326)

(4,62,549)

Total stockholders’ equity 

1,39,319

1,53,506

Total liabilities and stockholders’ equity 

$       1,42,969

$       1,63,182

 

Cypherpunk Technologies Inc.
Consolidated Statements of Operations
(in thousands, except share and per share amounts)

 

(Unaudited)

(Unaudited)

Three Months Ended June 30,

Six Months Ended June 30,

2026

2025

2026

2025

Operating expenses:

Research and development

$                  197

$             10,537

$                  358

$             23,448

General and administrative 

4,492

1,817

9,148

4,823

Restructuring charges

–

4,527

–

4,527

    Total operating expenses

4,689

16,881

9,506

32,798

Loss from operations

(4,689)

(16,881)

(9,506)

(32,798)

Interest income 

63

246

158

683

Interest expense

(6)

(7)

(13)

(13)

Australian research and development incentives

–

1

–

56

Change in fair value of embedded derivative

45,993

–

(31,562)

–

Foreign currency gain (loss)

1

(2)

1

(6)

Income (loss) before income taxes

41,362

(16,643)

(40,922)

(32,078)

Benefit from (provision for) income taxes

(1,973)

–

3,145

–

Net income (loss) attributable to common stockholders

$             39,389

$            (16,643)

$            (37,777)

$            (32,078)

Net income (loss) per share 

Basic 

$                 0.21

$               (0.40)

$               (0.21)

$               (0.78)

Diluted

$                 0.18

$               (0.40)

$               (0.21)

$               (0.78)

Weighted average common shares outstanding 

Basic

18,43,28,441

4,14,44,979

17,62,60,808

4,13,57,423

Diluted

21,73,43,013

4,14,44,979

17,62,60,808

4,13,57,423

 

 Leap Therapeutics, Inc. 
 Condensed Consolidated Statements of Cash Flows 
 (in thousands) 

 

 (Unaudited) 

 (Unaudited) 

 Three Months Ended June 30, 

 Six Months Ended June 30, 

2026

2025

2026

2025

 Cash used in operating activities 

$          (2,692)

$        (14,486)

$          (6,122)

$        (28,966)

 Cash used in investing activities 

(9,544)

–

(18,544)

–

 Cash provided by (used in) financing activities 

13,167

(119)

18,242

(180)

 Effect of exchange rate changes on cash and cash equivalents 

4

22

13

27

 Net increase (decrease) in cash and cash equivalents 

935

(14,583)

(6,411)

(29,119)

 Cash and cash equivalents at beginning of period 

6,689

32,713

14,035

47,249

 Cash and cash equivalents at end of period 

$           7,624

$          18,130

$           7,624

$          18,130

CONTACT:
Douglas E. Onsi
President & Chief Executive Officer
Cypherpunk Technologies Inc.
617-714-0360

For Investors:
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com

For Media:
Jacqueline Ortiz Ramsay
It Factor Strategies
954-294-3249
jacqueline@itfactorstrategies.com

 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/cypherpunk-technologies-reports-second-quarter-2026-financial-results-302849085.html

SOURCE Cypherpunk Technologies Inc.

Related Topics:
Continue Reading

Technology

Dingdong to Report Third Quarter 2026 Financial Results on November 12, 2026

Published

8 minutes ago

on

November 11, 2026

By

SHANGHAI, Nov. 10, 2026 /PRNewswire/ — Dingdong (Cayman) Limited (“Dingdong” or the “Company”) (NYSE: DDL), a leading fresh grocery e-commerce company in China, with advanced supply chain capabilities, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2026, before U.S. markets open on November 12, 2026.

About Dingdong (Cayman) Limited

Dingdong is the leading fresh grocery e-commerce company in mainland China, with sustainable long-term growth. The Company directly provides users and households with fresh groceries, prepared food, and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. Leveraging its deep insights into consumers’ evolving needs and its strong food innovation capabilities, Dingdong has successfully launched a series of private label products spanning a variety of food categories. Many of Dingdong’s private label products are produced at its own production plants, allowing it to more efficiently produce and offer safe and high-quality food products. Dingdong aims to be the first choice for fresh and food shopping.

For more information, please visit: https://ir.100.me.

 

View original content:https://www.prnewswire.com/news-releases/dingdong-to-report-third-quarter-2026-financial-results-on-november-12-2026-302935824.html

SOURCE Dingdong (Cayman) Limited

Continue Reading

Technology

Sanya hosts side event of the 7th Symposium on Global Maritime Cooperation and Ocean Governance

Published

1 hour ago

on

November 11, 2026

By

Report on Southeast Asian Youth Perceptions of Maritime Issues released

BEIJING, Nov. 10, 2026 /PRNewswire/ — A side event of the 7th Symposium on Global Maritime Cooperation and Ocean Governance was held at China Media Group (CMG) Sanya Studio on November 8. More than 10 Chinese and international participants discussed how to put into practice the Agreement under the United Nations Convention on the Law of the Sea on the Conservation and Sustainable Use of Marine Biological Diversity of Areas beyond National Jurisdiction (BBNJ Agreement), and how to communicate ideas about ocean conservation to audiences worldwide.

Experts at the event described the BBNJ Agreement, which entered into force in January this year, as a landmark victory for multilateralism in global ocean governance. They said it charts a course for all parties to work together to protect marine biodiversity.

Jiao Nianzhi, an academician of the Chinese Academy of Sciences, described marine biodiversity as a toolbox for humanity, saying that protecting it means safeguarding humanity’s future. Aileen Tan, chairperson of the Sub-Commission for the Western Pacific of UNESCO’s Intergovernmental Oceanographic Commission, said the BBNJ Agreement gives the ocean “breathing space” and stressed the need for scientists from different countries to work together on ocean conservation. She cited Malaysia-China cooperation in marine scientific research as a good example and expressed hope that China would play a greater leadership role. Ronán Long, director of the WMU-Sasakawa Global Ocean Institute at the World Maritime University in Sweden, said China’s strong data capabilities could help accelerate the implementation of the Agreement’s provisions on sharing non-monetary benefits arising from marine genetic resources.

Participants also highlighted China’s efforts and achievements in promoting maritime cooperation and advancing marine ecological restoration, among other areas. The side event was jointly hosted by CMG’s Chinese Language Programming Center, the Huayang Center for Maritime Cooperation and Ocean Governance, the National Institute for South China Sea Studies and other organizations.

During the symposium, CMG’s Chinese Language Programming Center and CMG Institute jointly released the Report on Southeast Asian Youth Perceptions of Maritime Issues. The report presents the concerns and expectations of young people in Southeast Asian countries, including Indonesia, Malaysia, Singapore and Thailand, regarding ocean-related issues.

The report finds that Southeast Asian youth have a positive outlook on maritime cooperation with China. Nearly 80 percent of respondents are willing to take part in China-ASEAN youth exchanges on ocean-related issues. The report also notes that Southeast Asian youth are concerned about broader issues of ocean governance and look to China to shoulder greater responsibilities and play a larger role in global ocean governance.

View original content to download multimedia:https://www.prnewswire.com/news-releases/sanya-hosts-side-event-of-the-7th-symposium-on-global-maritime-cooperation-and-ocean-governance-302935814.html

SOURCE China Media Group (CMG)

Continue Reading

Technology

Why Brisbane Airport selected LG for its landmark digital infrastructure upgrade

Published

1 hour ago

on

November 11, 2026

By

Australia’s third-largest airport now runs passenger information across 950 LG displays monitored centrally via LG SuperSign CMS

News summary

Brisbane Airport manages approximately 950 LG commercial displays from a single platform LG SuperSign CMS deployed on-premise to meet strict security and operational controls for critical infrastructureLG SuperSign CMS offers leadership, operations and ICT team remote visibility and control of entire display fleetLG’s embedded System-on-Chip allows real-time flight information (FIDS), gate information, wayfinding and operational messaging to be directly pushed to display screens without external media playersBrisbane Airport’s transition to LG’s SuperSign CMS has driven down operational costs significantlyDeployed in partnership with Australian integrator Programmed, this digital overhaul forms a key part of Brisbane Airport’s ongoing $5 billion Future BNE transformation

SYDNEY, Nov. 11, 2026 /PRNewswire/ — LG Electronics (LG) has partnered with Brisbane Airport Corporation (BAC), replacing a previously fragmented digital signage system with a modern network of approximately 950 LG commercial displays centrally managed by LG SuperSign CMS. Covering the domestic and international terminals, baggage handling areas, and car parks, these LG screens deliver real-time flight information displays (FIDS), gate information, passenger wayfinding, and operational communications reliably across a 24/7 environment.

As Australia’s third largest airport preparing for a forecast surge in passenger numbers ahead of the major event in 2032, Brisbane Airport needed to replace an increasingly unreliable, ageing network with a simplified, scalable solution that its lean ICT team could operate day-to-day.

“The reliability of the displays is essential. Without them working, people are lost — quite literally,” says Michael Kerr, Integrated Operations Manager at BAC.

To address these critical demands, LG worked alongside local integrator Programmed to deploy a centralised digital signage network driven by LG SuperSign CMS. The platform provides ICT and operations teams with comprehensive visibility across the entire display fleet remotely, replacing an otherwise manual process of physical, daily check-ups.

“LG SuperSign has been a game changer for my team. We just don’t have the arms and legs to go around and check those 950 screens on a daily basis. The monitoring capabilities really give us that eyes-on view of what’s across our infrastructure,” says Anthony Tully-Smith, ICT Applications Manager at BAC.

One system, diverse displays

BAC’s new estate involves a range of LG display solutions tailored to specific passenger zones. This includes:

43- and 49-inch LG commercial panelsLG Ultra Stretch displays in totemsLG 49XE-series high-brightness outdoor displays110-inch LG UM5K indoor screensA 136-inch LG LAPA-series All-in-One LED in international arrivals

With LG’s embedded System-on-Chip (SoC) platform and internal web page player, real-time flight information and content now play directly on the screens. This removes the need for external media players, simplifying the network architecture.

“We’ve taken what was a fragmented digital signage system, not very visible to management, now to an integrated modern solution with centralised management and health visibility,” says Graham Wands, Business Development Manager at Programmed. “LG SuperSign enables us to take a proactive stance and make sure that the FIDS and other signage are highly available and always visible to passengers.”

Built for critical infrastructure

As a privately owned critical infrastructure operator, BAC needed full control of its content. LG SuperSign CMS is deployed on-premise to meet the airport’s security and operational-control requirements. LG’s device hardening helps reduce the risk of unauthorised content, such as USB sideloading.

The project also supports the airport’s ESG goals; LG UH series screens carry Carbon Trust footprint-reduction certification, LG offers a free e-waste program, and power consumption can be monitored and optimised from LG SuperSign CMS.

“At an airport, a screen is only as useful as the information on it, and how quickly someone knows when it stops working. Brisbane Airport shows what happens when displays and management software are planned together as operational infrastructure, with a local integrator who knows the site. We’re grateful to Brisbane Airport and Programmed for the partnership, and we look forward to supporting the airport as it grows,” says Chris Wilson, Sales General Manager – Information Display at LG Electronics Australia.

Looking ahead

BAC sees LG as a long-term partner as it progresses its $5 billion Future BNE transformation, paving the way for the expansion of Terminal 3 and more LED and messaging capabilities ahead of the 2032 games. By transitioning from a fragmented legacy setup, BAC has unlocked a foundation built for long-term operational efficiency.

“For me, managing an ageing infrastructure before we moved to the new LG digital displays was costing us quite a lot from a maintenance and an ongoing perspective,” says Tully-Smith, “The move to the new LG SuperSign, but also the new LG screens, has driven down my operational cost significantly across the airport.”

This newfound efficiency has helped BAC focus on what’s most critical – passenger experience.

“It’s important for us to have a partner like LG. The innovation and the fresh thought that team brings has really helped me accelerate the digital experience across all of our terminals,” says Tully-Smith.

Read the full case study: LG Displays and SuperSign CMS power Brisbane Airport’s digital transformation

LG SuperSign CMS is purchased separately.

About LG Electronics
LG Electronics is focused on developing new innovations across information displays. We are committed to providing commercial electronic products that help businesses perform better. We offer a wide range of products, including information displays, digital signage for advertising, commercial system air conditioners, VRF systems and tailored solutions for different vertical markets.

About Brisbane Airport Corporation
Brisbane Airport Corporation (BAC), the operator of Brisbane Airport (BNE), is a private, unlisted Queensland company that proudly takes on the challenge of connecting Australia to the world. BAC’s passion and perseverance have cemented BNE as Queensland’s most important gateway, a leading hub for Australia, and an award-winning source of pride for its communities.

About Programmed
Programmed is a leading provider of Facility Management, Maintenance, and Staffing solutions across Australia and New Zealand. Programmed employs over 32,000 people every year across a broad range of industries and partners with more than 10,000 customers, small and large.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/why-brisbane-airport-selected-lg-for-its-landmark-digital-infrastructure-upgrade-302935816.html

SOURCE LG Electronics

Continue Reading

Trending